Several other equities research analysts have also recently commented on the company. Zacks Investment Research raised Novartis AG from a sell rating to a hold rating in a research note on Thursday, October 26th. Barclays PLC cut Novartis AG from an equal weight rating to an underweight rating in a research note on Wednesday, October 25th. Leerink Swann boosted their price target on Novartis AG from $89.00 to $91.00 and gave the company a market perform rating in a research note on Monday, October 23rd. BidaskClub raised Novartis AG from a sell rating to a hold rating in a research note on Saturday, August 19th. Finally, Cowen and Company set a $90.00 price target on Novartis AG and gave the company a hold rating in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, ten have given a hold rating and four have assigned a buy rating to the company. Novartis AG presently has an average rating of Hold and a consensus target price of $85.28.
Novartis AG (NVS) opened at $83.70 on Tuesday. The company has a market capitalization of $195.82 billion, a P/E ratio of 17.43, a P/E/G ratio of 2.64 and a beta of 0.72. The company has a quick ratio of 0.81, a current ratio of 1.08 and a debt-to-equity ratio of 0.32.
Novartis AG (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.04. The business had revenue of $12.41 billion during the quarter, compared to analysts’ expectations of $12.21 billion. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. The firm’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.23 EPS. equities analysts expect that Novartis AG will post 4.75 EPS for the current year.
Institutional investors have recently made changes to their positions in the business. Cetera Investment Advisers bought a new stake in Novartis AG during the second quarter worth approximately $241,000. Bartlett & Co. LLC boosted its position in shares of Novartis AG by 1.6% in the third quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock valued at $40,614,000 after acquiring an additional 7,249 shares during the period. Westwood Holdings Group Inc. boosted its position in shares of Novartis AG by 5.6% in the first quarter. Westwood Holdings Group Inc. now owns 5,405 shares of the company’s stock valued at $401,000 after acquiring an additional 285 shares during the period. GFS Advisors LLC boosted its position in shares of Novartis AG by 6.5% in the second quarter. GFS Advisors LLC now owns 21,314 shares of the company’s stock valued at $1,779,000 after acquiring an additional 1,300 shares during the period. Finally, Schafer Cullen Capital Management Inc. boosted its position in shares of Novartis AG by 9.2% in the second quarter. Schafer Cullen Capital Management Inc. now owns 2,780,606 shares of the company’s stock valued at $232,097,000 after acquiring an additional 233,292 shares during the period. 10.94% of the stock is owned by hedge funds and other institutional investors.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
What are top analysts saying about Novartis AG? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novartis AG and related companies.